LNWTC
NBIX icon

Laird Norton Wetherby Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$441K Sell
3,347
-135
-4% -$17.9K 0.01% 727
2025
Q4 		$494K Buy
+3,482
New +$504K 0.01% 718

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laird Norton Wetherby Trust Company's NBIX Position: Q1 2026 in Review

Laird Norton Wetherby Trust Company reduced its Neurocrine Biosciences (NBIX) stake by 3.9% in Q1 2026, selling an estimated $17.9K and leaving 3,347 shares worth $441K. The position accounts for 0.01% of the portfolio, ranked #727.

Laird Norton Wetherby Trust Company first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. The position peaked at $494K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Laird Norton Wetherby Trust Company held 3,347 shares of Neurocrine Biosciences worth $441K as of Q1 2026.
  • Laird Norton Wetherby Trust Company sold 135 Neurocrine Biosciences shares in Q1 2026, an estimated $17.9K.
  • Neurocrine Biosciences made up 0.01% of Laird Norton Wetherby Trust Company's portfolio in Q1 2026, its #727 holding.
  • Laird Norton Wetherby Trust Company first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Laird Norton Wetherby Trust Company's Neurocrine Biosciences position peaked at $494K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q1 2026, filed 15 May 2026.